271 related articles for article (PubMed ID: 24836153)
1. Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications.
Gerlinger M; Catto JW; Orntoft TF; Real FX; Zwarthoff EC; Swanton C
Eur Urol; 2015 Apr; 67(4):729-37. PubMed ID: 24836153
[TBL] [Abstract][Full Text] [Related]
2. Parallel evolution of tumour subclones mimics diversity between tumours.
Martinez P; Birkbak NJ; Gerlinger M; McGranahan N; Burrell RA; Rowan AJ; Joshi T; Fisher R; Larkin J; Szallasi Z; Swanton C
J Pathol; 2013 Aug; 230(4):356-64. PubMed ID: 23716380
[TBL] [Abstract][Full Text] [Related]
3. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.
Gulati S; Martinez P; Joshi T; Birkbak NJ; Santos CR; Rowan AJ; Pickering L; Gore M; Larkin J; Szallasi Z; Bates PA; Swanton C; Gerlinger M
Eur Urol; 2014 Nov; 66(5):936-48. PubMed ID: 25047176
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous challenges for urologic cancers.
Höglund M
Eur Urol; 2015 Apr; 67(4):738-9. PubMed ID: 25466939
[No Abstract] [Full Text] [Related]
5. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours.
Khalique L; Ayhan A; Weale ME; Jacobs IJ; Ramus SJ; Gayther SA
J Pathol; 2007 Feb; 211(3):286-95. PubMed ID: 17154249
[TBL] [Abstract][Full Text] [Related]
6. A transcriptomic intratumour heterogeneity-free signature overcomes sampling bias in prognostic risk classification for hepatocellular carcinoma.
Luo S; Jia Y; Zhang Y; Zhang X
JHEP Rep; 2023 Jun; 5(6):100754. PubMed ID: 37234275
[TBL] [Abstract][Full Text] [Related]
7. Emerging critical role of molecular testing in diagnostic genitourinary pathology.
Netto GJ; Cheng L
Arch Pathol Lab Med; 2012 Apr; 136(4):372-90. PubMed ID: 22458900
[TBL] [Abstract][Full Text] [Related]
8. Genomic and phenotypic heterogeneity in prostate cancer.
Haffner MC; Zwart W; Roudier MP; True LD; Nelson WG; Epstein JI; De Marzo AM; Nelson PS; Yegnasubramanian S
Nat Rev Urol; 2021 Feb; 18(2):79-92. PubMed ID: 33328650
[TBL] [Abstract][Full Text] [Related]
9. How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?
Soultati A; Stares M; Swanton C; Larkin J; Turajlic S
Curr Opin Urol; 2015 Sep; 25(5):358-66. PubMed ID: 26125509
[TBL] [Abstract][Full Text] [Related]
10. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
Barbieri CE; Chinnaiyan AM; Lerner SP; Swanton C; Rubin MA
Eur Urol; 2017 Feb; 71(2):237-246. PubMed ID: 27567210
[TBL] [Abstract][Full Text] [Related]
11. Intratumour heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligation-dependent probe amplification: a descriptive study.
Cuevas D; Velasco A; Vaquero M; Santacana M; Gatius S; Eritja N; Estaran E; Matias-Guiu X
Histopathology; 2020 Feb; 76(3):447-460. PubMed ID: 31550396
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA in prostate, bladder, and kidney cancer: a systematic review.
Catto JW; Alcaraz A; Bjartell AS; De Vere White R; Evans CP; Fussel S; Hamdy FC; Kallioniemi O; Mengual L; Schlomm T; Visakorpi T
Eur Urol; 2011 May; 59(5):671-81. PubMed ID: 21296484
[TBL] [Abstract][Full Text] [Related]
13. Urine microRNAs as potential noninvasive biomarkers in urologic cancers.
Mlcochova H; Hezova R; Stanik M; Slaby O
Urol Oncol; 2014 Jan; 32(1):41.e1-9. PubMed ID: 24035473
[TBL] [Abstract][Full Text] [Related]
14. Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy.
Heide T; Maurer A; Eipel M; Knoll K; Geelvink M; Veeck J; Knuechel R; van Essen J; Stoehr R; Hartmann A; Altmueller J; Graham TA; Gaisa NT
J Pathol; 2019 Jun; 248(2):230-242. PubMed ID: 30719704
[TBL] [Abstract][Full Text] [Related]
15. Intratumor heterogeneity: A new perspective on colorectal cancer research.
Zheng Z; Yu T; Zhao X; Gao X; Zhao Y; Liu G
Cancer Med; 2020 Oct; 9(20):7637-7645. PubMed ID: 32853464
[TBL] [Abstract][Full Text] [Related]
16. The complexity of prostate cancer: genomic alterations and heterogeneity.
Boyd LK; Mao X; Lu YJ
Nat Rev Urol; 2012 Nov; 9(11):652-64. PubMed ID: 23132303
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer intratumour heterogeneity: current status and clinical implications.
Joseph C; Papadaki A; Althobiti M; Alsaleem M; Aleskandarany MA; Rakha EA
Histopathology; 2018 Nov; 73(5):717-731. PubMed ID: 29722058
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA in prostate, bladder, and kidney cancer.
Martens-Uzunova ES; Böttcher R; Croce CM; Jenster G; Visakorpi T; Calin GA
Eur Urol; 2014 Jun; 65(6):1140-51. PubMed ID: 24373479
[TBL] [Abstract][Full Text] [Related]
19. Intratumor heterogeneity: evolution through space and time.
Swanton C
Cancer Res; 2012 Oct; 72(19):4875-82. PubMed ID: 23002210
[TBL] [Abstract][Full Text] [Related]
20. Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.
Pritchard AL; Johansson PA; Nathan V; Howlie M; Symmons J; Palmer JM; Hayward NK
PLoS One; 2018; 13(4):e0194098. PubMed ID: 29641532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
